A RANDOMIZED PHASE III STUDY OF IBRUTINIB PLUS OBINUTUZUMAB VERSUS IBRUTINIB PLUS VENETOCLAX AND OBINUTUZUMAB IN UNTREATED OLDER PATIENTS (≥ 70 YEARS OF AGE) WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

IRB/UVA Tracking #
21668
Contact
Sharon Lisa Johnson
Contact Phone
Phase
III
Primary purpose
Treatment
Cancer PI
Craig Portell
Status
OPEN TO ACCRUAL
Ages
Adult